Evolent Health (EVH) Net Income towards Common Stockholders (2014 - 2026)

Evolent Health has reported Net Income towards Common Stockholders for 13 years, with the latest figure at -$28.4 million in Q2 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 44.48% year-over-year to -$28.4 million in Q2 2026; TTM through Jun 2026 was -$511.1 million, a 175.97% decrease from a year earlier, with the FY2025 full-year figure at -$579.4 million, down 519.99% from the prior year.
• Net Income towards Common Stockholders was -$28.4 million for Q2 2026 at Evolent Health, down from -$26.6 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $2.1 million in Q3 2022, with the low at -$429.1 million in Q4 2025.
• Average Net Income towards Common Stockholders over 5 years is -$49.4 million, with a median of -$27.6 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders surged 116.28% in 2022, then tumbled 1663.64% in 2023.
• Over 5 years, Net Income towards Common Stockholders stood at -$11.3 million in 2022, then plunged by 264.75% to -$41.4 million in 2023, then gained by 26.04% to -$30.6 million in 2024, then slumped by 1301.7% to -$429.1 million in 2025, then surged by 93.39% to -$28.4 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$28.4 million (Q2 2026), -$26.6 million (Q1 2026), and -$429.1 million (Q4 2025), per Business Quant data.